218 related articles for article (PubMed ID: 25312676)
1. Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.
Rendle DI; Duz M; Beech J; Parkin T; Durham AE
J Vet Intern Med; 2015 Jan; 29(1):355-61. PubMed ID: 25312676
[TBL] [Abstract][Full Text] [Related]
2. BEVA primary care clinical guidelines: Diagnosis and management of equine pituitary pars intermedia dysfunction.
Menzies-Gow NJ; Banse HE; Duff A; Hart N; Ireland JL; Knowles EJ; McFarlane D; Rendle D
Equine Vet J; 2024 Mar; 56(2):220-242. PubMed ID: 37795557
[TBL] [Abstract][Full Text] [Related]
3. Investigation of rhythms of secretion and repeatability of plasma adrenocorticotropic hormone concentrations in healthy horses and horses with pituitary pars intermedia dysfunction.
Rendle DI; Litchfield E; Heller J; Hughes KJ
Equine Vet J; 2014 Jan; 46(1):113-7. PubMed ID: 23742059
[TBL] [Abstract][Full Text] [Related]
4. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
6. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
[TBL] [Abstract][Full Text] [Related]
7. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia.
Beech J; Boston R; Lindborg S; Russell GE
J Am Vet Med Assoc; 2007 Aug; 231(3):417-26. PubMed ID: 17669045
[TBL] [Abstract][Full Text] [Related]
8. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
Spelta CW; Axon JE
Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
McFarlane D; Banse H; Knych HK; Maxwell LK
J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
[TBL] [Abstract][Full Text] [Related]
10. Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction.
Copas VE; Durham AE
Equine Vet J; 2012 Jul; 44(4):440-3. PubMed ID: 21848531
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of combined testing to simultaneously diagnose pituitary pars intermedia dysfunction and insulin dysregulation in horses.
Horn R; Bertin FR
J Vet Intern Med; 2019 Sep; 33(5):2249-2256. PubMed ID: 31498947
[TBL] [Abstract][Full Text] [Related]
12. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
[TBL] [Abstract][Full Text] [Related]
13. The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses.
Lee ZY; Zylstra R; Haritou SJ
Vet J; 2010 Jul; 185(1):58-61. PubMed ID: 20537574
[TBL] [Abstract][Full Text] [Related]
14. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
[TBL] [Abstract][Full Text] [Related]
15. Equine pituitary pars intermedia dysfunction.
McFarlane D
Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
[TBL] [Abstract][Full Text] [Related]
16. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
Gehlen H; Fisch J; Merle R; Trachsel DS
J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515
[TBL] [Abstract][Full Text] [Related]
17. Effect of delayed plasma centrifugation on equine adrenocorticotropic hormone concentration.
Shepard KN; Haffner JC; Neal DL; Grubbs ST; Pearce GL
J Vet Diagn Invest; 2019 Jul; 31(4):585-587. PubMed ID: 31246158
[TBL] [Abstract][Full Text] [Related]
18. Comparison of cortisol and ACTH responses after administration of thyrotropin releasing hormone in normal horses and those with pituitary pars intermedia dysfunction.
Beech J; Boston R; Lindborg S
J Vet Intern Med; 2011; 25(6):1431-8. PubMed ID: 22092639
[TBL] [Abstract][Full Text] [Related]
19. The effect of freeze-thaw cycles on determination of immunoreactive plasma adrenocorticotrophic hormone concentrations in horses.
Hu K; Stewart AJ; Yuen KY; Hinrichsen S; Dryburgh EL; Bertin FR
J Vet Intern Med; 2020 May; 34(3):1350-1356. PubMed ID: 32255541
[TBL] [Abstract][Full Text] [Related]
20. The effects of sample handling and N-phenylmaleimide on concentration of adrenocorticotrophic hormone in equine plasma.
Rendle DI; Litchfield E; Gough S; Cowling A; Hughes KJ
Equine Vet J; 2015 Sep; 47(5):587-91. PubMed ID: 24980684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
